Volume 4.11 | Mar 22

Prostate Cell News 4.11 March 22, 2013
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
The E3 Ubiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity
Researchers demonstrated that the ubiquitin ligase Siah2 targets a select pool of NCOR1-bound, transcriptionally-inactive androgen receptor (AR) for ubiquitin-dependent degradation, thereby promoting expression of select AR target genes implicated in lipid metabolism, cell motility, and proliferation. [Cancer Cell] Abstract | Press Release

Detect 7 times more prostate epithelial progenitors with ProstaCult
PUBLICATIONS (Ranked by impact factor of the journal)


Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis and Circulating Tumor Cells in Prostate Cancer
Scientists report that the molecular chaperone Hsp27 drives epithelial-to-mesenchymal transition (EMT) in prostate cancer while its attenuation reverses EMT and decreases cell migration, invasion and matrix metalloprotease activity. [Cancer Res] Abstract

Regulation of Several Androgen-Induced Genes through the Repression of the miR-99a/let-7c/miR-125b-2 miRNA Cluster in Prostate Cancer Cells
Investigators report that androgen represses the miR-99a/let7c/125b-2 cluster through androgen receptor and anti-androgen drugs block the androgen-repression of the miRNA (microRNA) cluster. [Oncogene] Abstract

Activation of Protein Kinase CK2 Attenuates FOXO3a Functioning in a PML-Dependent Manner: Implications in Human Prostate Cancer
The authors propose a novel signaling axis apexed by deregulated Caseine Kinase II (CK2), dismantling the association of promyelocytic leukemia (PML) and PHLPP2 (they also report PHLPP2 to be a novel interacting partner of PML inside the nucleus), ultimately leading to the inactivation and nuclear exclusion of forkhead box O3 isoform a (FOXO3a), thereby downregulating p21/p27/Bim in which degradation of PML and the concomitant stabilization of active AKT plays a cardinal part. [Cell Death Dis] Full Article

A Novel Anti-Androgen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Investigators identified a novel anti-androgen, Compound 30, and compared its efficacy to MDV3100. They found that Compound 30 inhibits AR activity in LNCaP cells, C4-2 cells, as well as MDV3100 resistant cell lines. [Mol Cancer Ther] Abstract

The Impaired Viability of Prostate Cancer Cell Lines By the Recombinant Plant Kallikrein Inhibitor
Scientists demonstrated that different properties of the protease inhibitor recombinant kallikrein inhibitor may be explored for investigating the androgen-independent prostate cancer cell lines PC3 and DU145. [J Biol Chem] Abstract | Full Article

PPP2R2C Loss Promotes Castration-Resistant Prostate Cancer Growth and Is Associated with Increased Prostate Cancer-Specific Mortality
Researchers demonstrated that loss of PPP2R2C promotes androgen ligand depletion-resistant prostate cancer growth without altering androgen receptor (AR) expression or canonical AR-regulated gene expression. [Mol Cancer Res] Abstract

Parathyroid Hormone-Related Protein Regulates Integrin α6 and β4 Levels via Transcriptional and Post-Translational Pathways
Parathyroid hormone-related protein (PTHrP) enhances prostate cancer (CaP) growth and metastasis in vivo. PTHrP also increases cell survival and migration, and upregulates pro-invasive integrin α6β4 expression. The authors used the human CaP cell lines C4-2 and PC-3 as model systems to study the mechanisms via which PTHrP regulates α6β4 levels. [Exp Cell Res] Abstract


Extended Pelvic Lymph Node Dissection in Prostate Cancer: A 20-Year Audit in a Single Center
The authors evaluated 5274 prostate cancer patients treated with radical prostatectomy and anatomically extended pelvic lymph node dissection between 1990 and 2010. Year-per-year trends of clinical and pathological characteristics were examined. [Ann Oncol] Abstract

Sargramostim (GM-CSF) and Lenalidomide in Castration-Resistant Prostate Cancer (CRPC): Results from a Phase I-II Clinical Trial
In an effort to further evaluate the clinical and immune activity of granulocyte-macrophage colony-stimulating factor and lenalidomide, researchers conducted a Phase I-II trial in patients with CRPC. [Urol Oncol] Abstract

[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.


Delivering RNAi Therapeutics with Non-Viral Technology: A Promising Strategy for Prostate Cancer?
The authors discuss the potential of targeting oncogenes implicated in prostate cancer with RNA interference (RNAi)-based therapeutics using non-viral bioresponsive smart delivery systems that work in harmony with the physiological and biochemical environments of prostate tumors. [Trends Mol Med] Abstract

Zinc Transporters in Prostate Cancer
Zinc is transported by the SLC30 and SLC39 families of zinc transporters. However, in prostate cancer the intracellular zinc content is remarkably reduced and expression levels of certain zinc transporters are altered. The authors summarize the role of different zinc transporters in the development of prostate cancer. [Mol Aspects Med] Abstract


New Study Evaluates Incidence and Mortality of Prostate Cancer after Termination of PSA-Based Screening
Men who participate in biennial PSA based screening have a lower risk of being diagnosed as well as dying from prostate cancer up to nine years after their last PSA test. [Press release from the AlphaGalileo Foundation discussing research presented at the 28th Annual European Association of Urology (EAU) Congress, Milan] Press Release

Genetic Testing May Be Used to Identify BPH Patients with Increased Risk of Prostate Cancer
Patients with benign prostatic hyperplasia (BPH) carrying prostate cancer (PCa) a risk alleles are a potential target population for PCa screening and follow-up. Press release from EurekAlert discussing research presented at the 28th Annual European Association of Urology (EAU) Congress, Milan]
Press Release


GTx-758 Poster Presentation of Phase II Trial Data in Advanced Prostate Cancer Selected as One of the Best Posters at the 28th Annual European Association of Urology Congress
GTx, Inc. announced that its poster presentation entitled, “GTx-758, an ERα agonist, reduces serum free testosterone lower than can be achieved by leuprolide with a significantly lower rate of hot flashes in men with advanced prostate cancer”, was selected as one of the best posters at the 28th Annual European Association of Urology Congress held in Milan, Italy. [GTx, Inc.] Press Release

Nymox Receives Positive Interim Safety Review for Prostate Cancer Trial
Nymox Pharmaceutical Corp. said it has received positive interim safety review from the Independent Data Monitoring Committee for its prostate cancer trial. The committee has reported a third positive analysis of safety data from the clinical trial for the company’s Phase II study of NX-1207 for low risk localized prostate cancer. [Zacks Investment Research] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Gordon Research Conferences: Stem Cells & Cancer
April 21-26, 2013
Les Diablerets, Switzerland

our events page to see a complete list of events in the prostate cell community.


PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Genetic and Epigenetic Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

PhD Studentship – Detection of Novel Prostate Cancer Biomarkers (University of Bath)

PhD Studentship – Multi-Compartment Magnetic Resonance Imaging of Prostate Cancer (University of East Anglia)

Research Assistant – Prostate Cancer Vaccine Development (University of Oxford)

Principal Investigator – Ca2+ Channels on Tumor Angiogenesis (Lille 1 University)

Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us